This section hosts guidelines, manuals and toolkits to strengthen public health practice.
Women who are pregnant and have symptomatic coronavirus disease 2019 (Covid-19) are more likely than non-pregnant women to experience negative outcomes. Pregnant women have been advised to have the Covid-19 immunization in part as a result of these findings. However, compared to non-pregnant women, pregnant women's uptake has been lower. The barrier to maternity vaccination continues to be the safety concern of many women. This study, which involved pregnant women between the ages of 16 and 49, was retrospective, observational, and matched. This study compares the frequencies of 25 medically attended acute adverse events—including clinically significant outcomes and known reactogenic adverse events—among vaccinated women to matched unvaccinated controls. In subgroup analyses stratified by vaccination dose and mRNA vaccine manufacturer and comparing the incidence of outcomes in the two groups, relationships were comparable. A few of the study's limitations were the presence of wide confidence intervals around some rate ratios, the potential misclassification or incomplete capture of Covid-19 vaccine exposure or other covariates, and the potential underestimation of outcome incidence if the actual risk interval varied from the 21-day or 42-day interval used in this study. Acute adverse effects following the Covid-19 immunization that required medical attention soon before or during pregnancy were uncommon. The clinically significant acute adverse events that were assessed were not connected with higher risk after receiving the Covid-19 vaccination. The current data expand on the expanding body of research that supports the safety of receiving the Covid-19 vaccine while pregnant.